October 07, 2008
Home
About
Submit Press Release
PR Firms
Editors/Journalists
Search Archives
 
News Releases by Category  
News by Country  
News by MSA  
All News for Today  
Browse News by Day  
News by Trackbacks  
All Press Releases for December 21, 2004 Subscribe to this News Feed  
 

Beasley Allen Law Firm Calls Upon Pfizer for Celebrex Recall

Download this press release as an Adobe PDF document.

Experienced Celebrex attorneys have been reviewing patient cases against Pfizer since 2000.

Montgomery, AL (PRWEB) December 21, 2004 -- Tom Methvin, managing shareholder at Beasley Allen Law Firm, has called upon Pfizer to recall Celebrex. Our firm has been watching the situation unfold over the past 4 years. In light of the recent findings which undeniably link Celebrex to greater heart-attack risks, it is time for Pfizer to act responsibly and pull the drug from the market," said Mr. Methvin at a recent press conference.

Celebrex-Lawsuit-x220.jpg

Mr. Methvin said, and I believe they are making a careless decision in not doing so immediately.
According to a clinical trial conducted by the National Cancer Institute (NCI) and Pfizer, Inc., patients taking 400 mg of the drug twice daily had a 3.4 times greater risk of cardiovascular events compared to placebo. For patients in the trial taking 200 mg. twice daily, the risk was 2.5 times greater. The average duration of treatment in the trial was 33 months.

These findings are similar to recent results from a study of Vioxx (rofecoxib), another drug in the same class. Vioxx was recently voluntarily recalled by Merck in September. Another drug in this class, Bextra (valdecoxib) has shown an increased risk for CV events in patients after heart surgery. Bextra and Celebrex are the only two selective COX-2 agents currently on the U.S. market.

While Pfizer announced today that it would halt advertising of the drug, it appears they had little choice in that decision. The Food and Drug Administration said on Friday that it was considering regulatory measures that could include severe label warnings or even requiring that the drug be withdrawn in the United States.

Pfizer will inevitably have to recall Celebrex," Mr. Methvin said, and I believe they are making a careless decision in not doing so immediately."

Andy Birchfield, Beasley Allens lead Celebrex Litigation attorney, is spearheading the review of 383 cases, having filed 53 of those cases against Pfizer dating back to 2000.

For more information:
Andy Birchfield, Attorney
Beasley, Allen, Crow, Methvin, Portis & Miles, P.C.
1-800-898-2034 toll free
1-334-954-7555 fax
andy.birchfield@beasleyallen.com

Online Media Contact:
Jayme Yarroch
1-800-898-2343 toll free
1-334-657-8959 mobile
jayme.yarroch@beasleyallen.com
Beasley Allen Law Firm
Celebrex Lawsuit Information

# # #


See the original story at: http://www.prweb.com/releases/2004/12/prweb190805.htm
This press release was posted by the following PR Firm
Beasley Allen (View Listing in Directory of PR Firms)
 
Email this story to a colleague
Printer Friendly Version
Bookmark with del.icio.us
Bookmark with Y!MyWeb
Submit to Digg
Andy Birchfield
Beasley Allen Law Firm
1-800-898-2034
Email us Here

Celebrex Legal Information Screen Shot
Uploaded: Dec 21, 2004
File Name: CelebrexFull.jpg

If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these release. Our complete disclaimer appears here.
 
Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.
Please do not contact PRWeb®. We will be unable to assist you with your inquiry.
PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears here.

© Copyright 1997-2007, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Terms of Service | Privacy Policy | Copyright